99Tcmn-Dgdtc,a New Glucose Metabolic Agent,the Pharmacokinetics and Imaging Results

金仲慧,吕忠文,张卫方,张燕燕,盛晓燕,任佳蕾,张俊波
DOI: https://doi.org/10.3969/j.issn.1007-4287.2011.07.011
2011-01-01
Abstract:Objective To evaluate the pharmacokinetic characteristics and feasibility of imaging in tumor-bearing mice and rabbits of [99TcmN]2+ intermediate radiolabelled deoxyglucose dithiocarbamate(DGDTC).Methods The DGDTC was synthesized and radiolabelled with [99TcmN]2+ to form the 99 TcmN-DGDTC complex under the guideline of kit.Pharmacokinetics data of healthy rabbits were acquired by collecting radio counts of auricular vein and processed with software DAS2.1.1.Animal tumor model(10 mice with H22 transplanted cancer and 5 rabits with VX2 transplanted cancer) imaging was designed to two groups,99TcmN-DGDTC group and 99Tcm pertechnetate group(as a control).Scintigraphy was performed with blood flow,blood pool,and static acquisition continuously,till 2-4 hours after injection.Results The pharmacokinetics results were proved to be a two-compartment model,and t1/2 was 34.05 minutes.Scintigraphic results showed 99 TcmN-DGDTC complex could display tumor well in mice and rabbits tumor model.The count ratio of tumor to nontumorous tissue kept above 2 within 2 hours injected,suggesting the well tumor utilizing of 99 TcmN-DGDTC.Conclusion The pharmacokinetics results and scintigraphic findings supported the potential use of 99 TcmN DGDTC as a functional imaging agent.
What problem does this paper attempt to address?